HRMY
Harmony Biosciences Holdings, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Harmony Biosciences Holdings, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.
No other changes.
No other changes.
Last report0 of 7 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
+8.93%
vs ±14.3% implied · ×0.62
shaded = implied · ▲▼ = realized
Annual filing, covered
10-K parsed · Feb 24 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Feb 24 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
No thesis.
Harmony Biosciences Holdings, Inc.
37.90
pre 37.70 −0.55%
Expected move
Inputsspot 37.91exp Nov 20ATM strike 37.5ATM straddle 5.53IV 83%
No trades yet today.
No trades yet today.
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; of Harmony Biosciences Holdings, Inc.'s 6 closest co-movers, none share that code.
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; of Harmony Biosciences Holdings, Inc.'s 6 closest co-movers, none share that code.
Tall tick = annual report · Source: EDGAR
| Manager | Value | % base | |
|---|---|---|---|
| BlackRockindex-like | $258.6M | 13.02% | +0.45% |
| FMR | $130.1M | 6.55% | +13.19% |
| Vanguard Portfolioindex-like | $104.9M | 5.28% | +6.12% |
| American Century Companies | $92.5M | 4.66% | +20.63% |
| Dimensional | $87.1M | 4.39% | +15.27% |
| Manager | Value | % base | |
|---|---|---|---|
| BlackRockindex-like | $258.6M | 13.02% | +0.45% |
| FMR | $130.1M | 6.55% | +13.19% |
| Vanguard Portfolioindex-like | $104.9M | 5.28% | +6.12% |
| American Century Companies | $92.5M | 4.66% | +20.63% |
| Dimensional | $87.1M | 4.39% | +15.27% |
Bull1
Bear2